Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
good find on Genetech/Roche article ... will cause more eyes to focus on B in other IBD indication and Super-drug Status.
...and you are guessing No Consultants? How did he get this far with him and jane then?...IMO just logical that there are many more behind the scenes.
RBL labs are huge building (for containment) but small labs...they take time ... especially if they are doing a number of tests.
Leo has no control...and IMO counter-productive to rush them or harass them.
IMO Fatal error to assume there will be only 2 or 3 employees at the right time! If there are contract/consultants who are prominent, in a minute, and the signing of a contract, they can become employees...
IMO...with all data in and anticipated moves by LEO...detractors will be caught with their pants down, tripping and falling as they try to run away from the embarrassment of their lies and folly ...
...esp with only 330M shares and $80M Market Cap!...and another OTC Stock (at below .04 a month ago) with 2.1B shares and now 1.5 Billion Market cap...being 1/3 the drug that Brilacidin is for COVID-19...and without the other indication of B (IBD)!
...that movement alone would be a 20 X (or $4.80 a share) from here for IPIX.
...employees beyond those listed is all that is needed. A stealth and cleaver/fiscally responsible move is to have several top consultants on piece-meal/special project work until the right time.
He appears to contract out many functions...so IMNO that appears to be Leo's style...a fugile and intelligent one.
FIRST THERE WAS A BUYER... on the fill...begging for the shares...anyone of the FUDSTERS...could have filled it for "effect" to continue your campaign of misinformation...
Actually I have an large order in lower...care to fill me lower in volume?
"Phase III readouts spell disaster for Genentech’s lead IBD drug!"
https://endpts.com/phase-iii-readouts-spell-disaster-for-genentechs-lead-ibd-drug/
Huge news for IPIX...and Brilacidin in the IBD indication!
As Brilacidin's success against COVID-19 comes to the forefront...IMO many BP will take a look at Brilacidin in the other indications it has been successful in...which is ALL of the indications for which Phase II human trials have already been completed ... and as we know all have been successful in reaching their efficacy end points.
IMO look for a nice halo effect over Brilacidin...
huge news for IPIX...and Brilacidin in the IBD indication!
As Brilacidin's success against COVID-19 comes to the forefront...IMO many BP will take a look at Brilacidin in the other indications it has been successful in...which is ALL of the indications for which Phase II human trials have already been completed ... and as we know all successful
IMO look for a nice halo effect over Brilacidin...
I can point to multiple SH who can play (manipulate) with SP...like you
Ups and downs...meaningless right now...(except to the flipper...who chip pennies...no big deal for those who know what they own!
...with delivery of standard medical research documentation...IPIX can and will graner strong interest from Hospitals and their clinical trial staff. PR's are investor/consumer teasers...
Proper documentation and presentations of Results from RPL's and prior FDA human trials will grab attention by Trial sites and their staff.
IMO...IPIX has their attention...otherwise there could not be a reference to Trials in 4th quarter (which I believe will be announced in 3rd quarter)
"IP needs a B for C inhaler prophylaxis trial and instead we are about to start an IV B trial in hospitalized patients."
...you go first with what you have (fastest way to trials) and develop in parallel inhaler delivery... We have a researcher at RBL who has a grant (via D of Defence) for such delivery and have the same researcher excited about Brilacidin's responsiveness...how much of a stretch would it be to expect the two research projects to meet?
and oh ... inhaler has already been PR'd
...the book you wrote..."Lizzi & Fedl"?
...not exactly correct. IPIX has already PR'd that Human Trial locations are being lined up...which is occuring before the actual Peer Review Publication...
An Investigative Brochure (IB) will be prepared when the company has the final data from the RBl detailing every fact, trial and test results of Brilacidin and mechanisms/anticipated results as well as proposed protocol...and is submitted to the prospective site for Human Trials as well as to the FDA upon which FDA will review and make its final determination for IND/EUA approval of Human Trials...The information should detail all the data received and added to from the RBl (is what IPIX is waiting for) ... the Data is important...not the Peer review article discussing that data.
If your friend and/or his clinical trial staff received the IB...IMO..he would quickly change his tune.
Just my opinion...
I assume it wasn't ready since the final data from the RBL has not been announced as received by IPIX...when you read in a PR that final data has been received (and the results)... I would expect it to be the signal that the fuse has been lit and chain reaction to commence...the IB would be going to the proposed trial sites and FDA would receive application for IND/ENU.
...no question hype can drive it well over its realistic SP...most otc investors invest on how cheap SP appears in dollar terms...not actual value...
Those who were around in 2000 market know that...they also know the drop when the music stopped!.
GILD has a PE of 10... SP of $70 represent annual earnings $7.00 per share
IF RLFTF had a PE of 10 (based upon Annual EBITDA of $200M on a gross
$300M?)...
SP would be limited to less than $1.00 per share, coincidently it topped out last Thursday at ...$.95 per share
IMO...not a coincidence.
TCM55 is correct in his calculation...based upon $2 pps.
Inaccurate inferences in your questions again:
1. Has it even started the clinical trials phase 1 trials?...It has already passed PHASE I Safety through 3 other indications in which it passed safety and moved on and passed Phase II...it will enter Phase II on COVID-19 Human trials.
2. Tests done by U.S. Regional Biocontainment Labs were on Human Lung Tissue (2x) and Human Liver Tissue (1x) all evidence of 905 + reduction in Covid-19 viral load (Remdesivir only showed 50% reduction) (no "mice" testing on Covid...live human tissue)
3. Do they have the funds to conduct trials? Yes
4. You forgot to ask if it did more than RLFTF...YES! It has unique (3 in 1 combination: antiviral(destroys and prevents replication and mutation) , immune/anti-inflammatory, and antimicrobial... a DYNAMIC anti-COVID-19 therapeutic candidate.
...if requested...they would IN ADDITION TO
their own separate clinical trials...
no..."C" sucks!
...another poster mentioned it. I'm not dissing RLFTF...just making a comparison...as to which would have the greater success...imho...IMO...both will establish efficacy. (both far superior to Remdesivir).
Phase 1 is "Safety" and THE OTHER has already established "safety" in THE OTHER via FDA Human Trials (over 500 patients...on three other indications...
There appears no reason (based on FDA criteria) that It's Human Trials for Covid-19 would not start Phase II on approval of IND.
Not a completely true statement...
I would concur with your statements with one qualification:
...what will be more fun is when IPIX PR's the significant difference and extremely more robust nature and action of Brilacidin over the new girl in town.
IMO...Brilacidin will prove infinitely more effective with its three prong action...as it destroys COVID-19 (lab results)...vs prevents replication.
Key difference is in the May 26th PR.
"“We now have preliminary in vitro data from two separate independent laboratories that, cumulatively, support Brilacidin’s ability to act directly on the novel coronavirus, as a virucidal agent, and prevent viral binding to host cells."
KEY DIFFERENCE: Brilacidin is a virucidal (destroys)...THE OTHER NEW GIRL IN TOWN "inhibits"...no evidence that it "destroys"...it has not claimed to be "virucidal."
As noted in later PRs...
“Brilacidin has now demonstrated potent inhibition of SARS-CoV-2 in human lung and kidney cell lines, and in VERO cells, in laboratory testing conducted by independent academic researchers at two institutions, both of whom plan to submit their findings for peer-review publication,”
...and further more...INTEREST IN BRILACIDIN EXTENDS BEYOND COVID-19...into NEW POTENTIAL VIRAL THREATS...
"... federal grant application that was submitted last week by the RBL, in collaboration with the Company, proposing to evaluate Brilacidin’s potential as a pan-coronavirus therapeutic, with possible extension into other viruses."
I am anticipating 5X to 10X greater positive reaction to Brilacidin...as its mechanism and efficacy proves out in Human Clinical Trials. (of course IMO)
...because he is a technical trader...very bullish move (confirmed) over .27
"Another scary enveloped virus from China"....
That is the edge and its a big one which Brilacidin has over newcomers...
Brilacidin, from day one of development by Dr. DeGrado, was formulated to kill and destroy ANY "ENVELOPED VIRUS" existing when formulated or future "Enveloped Virus"...
REMEMBER: Viral cells are attracted to Brilacidin...and Brilacidin "pops the envelope (destroying it), like "a pin pops a balloon"
Destroying the virus on contact...obviously prevents replication and speed of destruction eliminates mutation.
Brilacidin already present in tissue has been shown in RBL tests...to act as a prophylactic (not unlike a Vaccine which develops antibodies which should do the same as Brilacidin...if vaccine works!)
Other potential therapeutics have not shown they could do the same. The mechanism of action appears to be unique to Brilacidin (as was planned when formulated).
Brilacidin was developed as a new synthetic Antibacterial and at the time of development was believed and proving to be a new and effective Antiviral.
"We don’t even have Brilacidin readily available for trials."
You don't know that! Perhaps its not been PRd and will in proper context...
...IMO...its in the cards...Leo has expressed in PRs that he wants as much data from Gov. Labs as is expected...once received there is no reason not to apply for IND and EMA...
PRs indicated testing through August...perhaps they will be done mid month...nobody knows...but we do have an outside date
IMO...he won't hesitate once additional data is received.
...IMO...its in the cards...Leo has expressed in PRs that he wants as much data from Gov. Labs as is expected...once received there is no reason not to apply for IND and EMA...
IMO...he won't hesitate once additional data transmitted.
Brilacidin is...non-toxic vs Remdesivir shows toxicity over 50mg. Brilacidin did not show toxicity (I believe it was) up to the 250mg dosage tested in previous trials.
Testing on Human Lung Tissue is extremely more difficult than monkey tissue ...which many tests use for other candidate drugs...and Brilacidin has shown to be extremely effective in gov. labs using Human Tissue...specifically lung.
...nope...they are not in the business of investing...only looking for arbitrage play...they get in (put to them) and out on the spread...and they are not interested taking in risk ... not their game, not investment bankers
...there was never Covid-19 before...and IPIX/Brilacidin was never a top prospective pick with all positive testing results to cure a pandemic!
YES...A BEAUTIFUL CHART IN WHICH TO BLOW AWAY THE NAYSAYERS...
Many charts that looked dire in this space before have blown the lid off the technicials...IMO we will have a very interesting and fruitful end of August and beginning of September...don't think we will have to wait until 4th quarter for our reward to begin in earnest.
NOT TOXIC FINANCING...FAVORABLE FINANCING DEAL....
IPIX decides the PRICE...and when to PUT the STOCK to them...if at all
Good back-stop...to have money available if and when needed.
They can PUT NONE TO THEM...or all at $5.00 if and when when the time comes...
IMO... Grant of FDA-IND for Brilacidin = $2.30-$3.00 which would be an equivalent move for the other stock which was .043 a week ago.
AND FOR THOSE CRYING..about the share count of IPIX at 330M shares...the other has 2.1 BILLION SHARES starting at .043...rose to .40 on IND announcment.
...so there is the roadmap for IPIX HOLDERS! IMO looking at 10X (1000%) on FDA/IND approval...IMO...weeks away!
Brilacidin ... will show more dynamic action against Covid-19...and move much higher...
Look for a move toward that 1000% which is likely going to be sooner than later...
Looks like the other went from $90M to over $900M this morning and possibly to $1B today with reporting of FDA IND approval use... Success of one does not cancel out the other...and in this case will validate Brilacidin potential and price action to come.
Reporting FDA IND grant, with same action, would move IPIX from $.23 to $2.30 - $3.00 with anticipated Brilacidin FDA IND announcement...
IMO...not if, but when....and not long to wait folks...
If you read ANY of the RPT test results...it Brilacidin "Kills" and DESTROYS the virus...which goes way BEYOND BLOCKING REPLICATION...how can something DEAD REPLICATE?
IMO...Just the announcement of commencement of Human Trials should propel IPIX to at least $1.25...in the short run.
This was recently demonstrated by another Microcap Antiviral Stock with similar action against Covid-19... which went from .043 and has settled at .21, a 5X bagger for beginners.
"I think B might have a greater effect on Covid than that. IF the data purported by Leo is true."
You are correct...the expectations (based on the resulting RBL tests) is that it will "KILL" the viral cells...therefore will "CURE" the infected patient!
The "prophylactic effect" occurs when Brilacidin is already introduced in the body and is present...Covid-19 entering the body will be killed...also proven out in RBL tests...
...but the ultimate definitive proof will be human trials.
ps. "IF the data purported by Leo is true"...incorrect... the DATA is from the RBL (independent bodies) are presumed to be true...Leo/IPIX is only reporting what the RBLs conclude.
IMO...your thought process is well accurate... the contrary would have to assume that the lead GMU Researcher who is actively reporting on Brilacidin Covid-19 testing (and other pathogens) cannot make the leap of using Brilacidin on another grant study result on an Aerosolized Delivery System for anti-virals/anti-pathogens...
She would have to be brain dead ... not to have suggested review of potential for Brilacidin...and company most likely referenced Brilacidin's potential delivery via an aerosolized method...because it was being suggested or being investigated by GMU.
IPIX (and predecessor Poly) ...have always contended Brilacidin is relatively inexpensive to mgf and produce...(esp. in comparison to Remdesivir)
IMO...another huge plus of interest by those making decisions at the very top.
IPIX (and predecessor Poly) ...have always contended Brilacidin is relatively inexpensive to mgf and produce...(esp. in comparison to Remdesivir)